An interventional study of Halova vaginal ovules and Estriol 0.5 mg vaginal ovules in Genitourinary Syndrome of Menopause (GSM), Vaginal Dryness and Vulvo Vaginal Atrophy (VVA), sponsored by Perfect Care Distribution. Completed at 1 site in Romania. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Perfect Care Distribution · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study was to compare Halova vaginal ovules, a non-hormonal medical device, with vaginal estriol 0.5 mg, an estrogen treatment, for genitourinary symptoms in postmenopausal women.
The main questions were:
Participants:
This completed, single-center, post-market clinical study compared Halova vaginal ovules with Ovestin vaginal ovules containing estriol 0.5 mg in women with postmenopausal genitourinary symptoms. The study combined randomized and nonrandomized allocation according to participants' acceptance of hormonal therapy.
Women willing to receive either intervention were randomized 1:1 to Halova or estriol using computer-generated permuted blocks of four. Women who declined hormonal therapy were assigned directly to Halova. The study enrolled 252 participants: 55 randomized to Halova, 56 randomized to estriol, and 141 assigned directly to Halova. Overall, 196 participants received Halova and 56 received estriol.
The main comparative clinical analyses in the study report used the randomized subset of 111 participants. Analyses of the full cohort provided supportive information on clinical outcomes and tolerability. Participants assigned directly to Halova were analyzed separately from the randomized Halova group for the main treatment comparison.
Both interventions followed the same 12-week administration schedule: one ovule intravaginally daily for the first two weeks, followed by one ovule twice weekly until Week 12. Participants were aware of their treatment because the formulations and primary packaging differed. Clinical outcome assessors were blinded to treatment assignment. Treatment packs and educational materials were prepared by personnel who did not perform the clinical assessments.
Clinical assessments were performed at baseline, Week 12, and Week 24. The primary outcomes at Week 12 were changes in the Most Bothersome Symptom score, the study-adapted Vaginal Health Index total score, and its ordinal pH component score. Follow-up at Week 24 assessed persistence of treatment effects. Sexual function was evaluated using the Female Sexual Function Index. Endometrial thickness was assessed by transvaginal ultrasound at baseline, Week 12, and Week 24.
Safety was assessed in all treated participants through documentation of adverse events during clinical visits and telephone monitoring. Telephone contacts at Weeks 2, 4, and 8 also assessed adherence, tolerability, and satisfaction.
All participants received the same individualized educational counseling and written menopause-related materials. A study-specific knowledge, attitudes, and behaviors questionnaire was administered at baseline before counseling and again at Week 12. The educational component was evaluated through a before-and-after assessment within the cohort; there was no separate group that did not receive education.
159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.
This study's enrollment of 252 is above the median of 64 across 127 interventional studies indexed under Dyspareunia.
Browse Dyspareunia studies →Perfect Care Distribution is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants willing to receive either treatment who were randomized to Halova vaginal ovules. This arm included 55 participants.
Device: Halova vaginal ovules · Behavioral: Menopause-related education and counseling
Participants willing to receive either treatment who were randomized to Ovestin vaginal ovules containing estriol 0.5 mg. This arm included 56 participants.
Drug: Estriol 0.5 mg vaginal ovules · Behavioral: Menopause-related education and counseling
Participants who declined hormonal therapy and were assigned directly to Halova vaginal ovules without randomization. This arm included 141 participants.
Device: Halova vaginal ovules · Behavioral: Menopause-related education and counseling
Halova is a vaginal medical device formulated as ovules containing sodium hyaluronate (5 mg per ovule) and xylitol (3 mg per ovule), together with semi-synthetic glycerides, lanolin, Aloe vera oil extract, Calendula officinalis extract, colloidal silicon dioxide, and vitamin E. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.
Each Ovestin vaginal ovule contained estriol 0.5 mg. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.
All participants received individualized counseling and written educational materials about menopause, genitourinary symptoms, and available management options. A study-specific questionnaire was administered before the educational intervention at baseline and again at Week 12. This intervention was common to all three allocation arms.
Change From Baseline in Most Bothersome Symptom (MBS) Score at Week 12
At baseline, each participant identified the genitourinary symptom causing the greatest discomfort, such as vaginal dryness, dyspareunia, or urinary symptoms. The same symptom was reassessed at Week 12 using an 11-point numerical rating scale from 0 (symptom absent) to 10 (maximum severity). Improvement was calculated as the baseline score minus the Week 12 score, with positive values indicating reduced symptom severity.
Time frame: Baseline and Week 12
Change From Baseline in Study-Adapted Vaginal Health Index (VHI) Total Score at Week 12
Vaginal health was assessed using a study-adapted version of the Vaginal Health Index (VHI), as defined in the study-specific standardized clinical assessment guide. Five parameters were evaluated: vaginal elasticity, moisture, vaginal pH category, epithelial integrity, and inflammation. Each parameter was scored from 0 (severely impaired) to 5 (normal). The total score was the sum of the five component scores and ranged from 0 to 25, with higher scores indicating better vaginal health. Change was calculated as the Week 12 total score minus the baseline total score, with positive values indicating improvement.
Time frame: Baseline and Week 12
Change From Baseline in Vaginal pH Component Score of the Study-Adapted VHI at Week 12
Vaginal pH was summarized using the ordinal pH component of the study-adapted VHI. Scores ranged from 0 to 5: 5 for pH 4.5 or lower; 4 for pH above 4.5 to 5.0; 3 for pH above 5.0 to 5.5; 2 for pH above 5.5 to 6.0; 1 for pH above 6.0 to 6.5; and 0 for pH above 6.5. Higher scores indicated a more favorable vaginal pH category. Change was calculated as the Week 12 component score minus the baseline score, with positive values indicating improvement. The analyzed outcome was the component score rather than the raw numerical pH value.
Time frame: Baseline and Week 12
Change From Baseline in Female Sexual Function Index (FSFI) Total Score at Week 12
Female sexual function was assessed using the 19-item Female Sexual Function Index (FSFI), covering desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores ranged from 2 to 36, with higher scores indicating better sexual function. Change was calculated as the Week 12 total score minus the baseline total score, with positive values indicating improvement. The main FSFI analysis included participants with calculable total scores; analysis restricted to participants sexually active at baseline was supplementary.
Time frame: Baseline and Week 12
Change From Baseline in Most Bothersome Symptom (MBS) Score at Week 24
At baseline, each participant identified the genitourinary symptom causing the greatest discomfort, such as vaginal dryness, dyspareunia, or urinary symptoms. The same symptom was reassessed at Week 24 using an 11-point numerical rating scale from 0 (symptom absent) to 10 (maximum severity). Improvement was calculated as the baseline score minus the Week 24 score, with positive values indicating reduced symptom severity.
Time frame: Baseline and Week 24
Change From Baseline in Study-Adapted Vaginal Health Index (VHI) Total Score at Week 24
Vaginal health was assessed using a study-adapted version of the Vaginal Health Index (VHI), as defined in the study-specific standardized clinical assessment guide. Five parameters were evaluated: vaginal elasticity, moisture, vaginal pH category, epithelial integrity, and inflammation. Each parameter was scored from 0 (severely impaired) to 5 (normal). The total score was the sum of the five component scores and ranged from 0 to 25, with higher scores indicating better vaginal health. Change was calculated as the Week 24 total score minus the baseline total score, with positive values indicating improvement.
Time frame: Baseline and Week 24
Change From Baseline in Vaginal pH Component Score of the Study-Adapted VHI at Week 24
Vaginal pH was summarized using the ordinal pH component of the study-adapted VHI. Scores ranged from 0 to 5: 5 for pH 4.5 or lower; 4 for pH above 4.5 to 5.0; 3 for pH above 5.0 to 5.5; 2 for pH above 5.5 to 6.0; 1 for pH above 6.0 to 6.5; and 0 for pH above 6.5. Higher scores indicated a more favorable vaginal pH category. Change was calculated as the Week 24 component score minus the baseline score, with positive values indicating improvement. The analyzed outcome was the component score rather than the raw numerical pH value.
Time frame: Baseline and Week 24
Change From Baseline in Female Sexual Function Index (FSFI) Total Score at Week 24
Female sexual function was assessed using the 19-item Female Sexual Function Index (FSFI), covering desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores ranged from 2 to 36, with higher scores indicating better sexual function. Change was calculated as the Week 24 total score minus the baseline total score, with positive values indicating improvement. The main FSFI analysis included participants with calculable total scores; analysis restricted to participants sexually active at baseline was supplementary
Time frame: Baseline and Week 24
Change From Baseline in Endometrial Thickness at Week 12
Endometrial thickness was measured in millimeters by transvaginal ultrasound. Change was calculated as the Week 12 measurement minus the baseline measurement; positive values indicated increased thickness. The quantitative analysis included participants with measurable values greater than zero at both assessments. Zero values treated as not applicable in the context of an absent uterus were excluded from this continuous analysis. Clinically relevant individual findings were also documented in the safety record.
Time frame: Baseline and Week 12
Change From Baseline in Endometrial Thickness at Week 24
Endometrial thickness was measured in millimeters by transvaginal ultrasound. Change was calculated as the Week 24 measurement minus the baseline measurement; positive values indicated increased thickness. The quantitative analysis included participants with measurable values greater than zero at both assessments. Zero values treated as not applicable in the context of an absent uterus were excluded from this continuous analysis. Clinically relevant individual findings were also documented in the safety record.
Time frame: Baseline and Week 24
Number of Participants With Adverse Events During the Study
Safety was assessed by documenting adverse events reported by participants or identified during clinical assessments and telephone follow-up, regardless of the suspected relationship to treatment. The outcome was the number and percentage of treated participants experiencing at least one adverse event. Events were characterized by seriousness, severity, suspected relationship to the assigned intervention, action taken, and outcome. Safety summaries included all treated participants, with separate reporting for the randomized subset when appropriate.
Time frame: From baseline through Week 24
Change From Baseline in Item-Level Responses to a Menopause-Related Knowledge, Attitudes, and Behaviors Questionnaire at Week 12.
Participants completed a study-specific questionnaire at baseline, before individualized educational counseling and receipt of written educational materials, and again at Week 12. The questionnaire assessed recognition of menopause-related symptoms, associated health risks, and management options, as well as perceptions and behaviors related to menopause. For each item, outcomes were the number and percentage of participants selecting each response option at baseline and Week 12, and the change in these percentages between assessments. For questions allowing multiple responses, each option was evaluated separately. No composite scoring algorithm was prespecified in the study protocol.
Time frame: Baseline and Week 12
Self-Reported Adherence to the Assigned Intervention at Week 2
Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 2. The denominator was the number of participants with available adherence data at that assessment
Time frame: Week 2
Self-Reported Adherence to the Assigned Intervention at Week 4
Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 4. The denominator was the number of participants with available adherence data at that assessment.
Time frame: Week 4
Self-Reported Adherence to the Assigned Intervention at Week 8
Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 8. The denominator was the number of participants with available adherence data at that assessment
Time frame: Week 8
Self-Reported Adherence to the Assigned Intervention at Week 12
Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 12. The denominator was the number of participants with available adherence data at that assessment.
Time frame: Week 12
Participant-Reported Treatment Satisfaction at Week 12
Participants reported overall treatment satisfaction using five response categories: very satisfied, satisfied, no opinion, dissatisfied, or very dissatisfied. The outcome was the number and percentage of evaluable participants in each response category at the end-of-treatment assessment. Positive satisfaction was summarized as the number and percentage selecting very satisfied or satisfied.
Time frame: Week 12
Plan to share: No — There is no plan to share individual participant data. Study findings will be reported in aggregate form in scientific publications.
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Apr 2026, 13 months.
Of 60 interventional studies with no phase under Dyspareunia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 38. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Perfect Care Distribution